Meteora Capital’s SAB Biotherapeutics SABS Stock Holding History

Meteora Capital’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,452	Closed	-$59.2K	–	398
2023 Q1	$59.2K	Hold	13,452	–	–	0.01%	258
2022 Q4	$79.4K	Sell	13,452 -11,501	-46%	-$105K	0.02%	201
2022 Q3	$175K	Sell	24,953 -4,301	-15%	-$42.7K	0.04%	198
2022 Q2	$424K	Buy	+29,254	New	+$614K	0.08%	180

Other funds holding SABS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

IFAM

Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Meteora Capital's SABS Position: Q2 2023 in Review

Meteora Capital sold out of SAB Biotherapeutics (SABS) in Q2 2023, closing a stake of 13,452 shares — an estimated $59.2K sold.

Meteora Capital first reported a position in SABS in Q2 2022 and held it in 4 quarters. The position peaked at $424K in Q2 2022. 38 funds tracked by Wall St. Rank hold SABS as of Q2 2023.

Meteora Capital reported no remaining SAB Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Meteora Capital sold 13,452 SAB Biotherapeutics shares in Q2 2023, an estimated $59.2K.
Meteora Capital first reported a position in SAB Biotherapeutics in Q2 2022 and held it in 4 quarters.
Meteora Capital's SAB Biotherapeutics position peaked at $424K in Q2 2022.
38 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2023.

Based on Meteora Capital's 13F filing for Q2 2023, filed 14 Aug 2023.